Key Highlights
- Vyne Therapeutics shares fell approximately 4% in pre-market trading.
- Shareholders approved issuing shares to Yarrow equity holders, a key prerequisite for the merger.
- A share consolidation was ratified, with the board to set a final ratio between 1-for-10 and 1-for-70.
- Shareholders also approved expanding authorized common stock to 300 million shares.
Vyne Therapeutics (NASDAQ: VYNE) shares fell approximately 4% in pre-market trading after the company convened a special meeting of shareholders to deliberate on proposals tied to its merger with Yarrow.
What Happened
Investors granted approval for issuing shares to Yarrow equity holders, fulfilling a vital prerequisite for finalizing the business combination.
A share consolidation was ratified, with the Board of Directors authorized to determine a final ratio between 1-for-10 and 1-for-70 at a later date. Shareholders also voted to expand the total authorized common stock to 300 million shares.
Market Reaction
Shares fell approximately 4% in pre-market trading, even as shareholders approved the key proposals needed to advance the Yarrow merger.
Outlook
The Board of Directors is authorized to determine a final reverse split ratio between 1-for-10 and 1-for-70 at a later date, ahead of finalizing the business combination with Yarrow.
What did Vyne Therapeutics shareholders approve?
Shareholders approved issuing shares to Yarrow equity holders, a share consolidation with a ratio to be set by the board between 1-for-10 and 1-for-70, and an increase in authorized common stock to 300 million shares.
Why did Vyne Therapeutics shares fall 4% pre-market?
Shares fell even as shareholders approved the proposals needed to advance the merger with Yarrow.
What reverse split ratio range was approved?
The Board of Directors was authorized to determine a final ratio between 1-for-10 and 1-for-70.






Please wait processing your request...